RSNA MIDRC Data Contribution Hits 30,000

After less than two years of data collection and processing, the Radiological Society of North America (RSNA) has successfully delivered over 30,000 de-identified imaging exams to the Medical Imaging and Data Resource Center (MIDRC), an open-access platform which publishes data to be used for research.

The RSNA contribution includes COVID-19 patient chest X-ray and CT images solicited from sites around the world. Each image dataset contains patient demographics and is accompanied by relevant clinical data points including hospital and ICU admission and discharge, as well as breathing support provided.

“RSNA is delighted to collaborate on the development of MIDRC,” said Curtis P. Langlotz, M.D., Ph.D., RSNA Board liaison for information technology and annual meeting and professor of radiology and biomedical informatics, director of the Center for Artificial Intelligence in Medicine and Imaging and associate chair for information systems in the Department of Radiology at Stanford University. “MIDRC is a massive, curated, diverse, multi-institutional imaging dataset that enables new insights about the diagnosis and prediction of COVID-19 infection, its complications and its outcomes. From the release of the first set of images to today, we are realizing the benefits of new algorithms and the resulting innovations in machine learning.”

MIDRC is funded by the National Institute of Biomedical Imaging and Bioengineering, hosted by the University of Chicago, and jointly developed by RSNA, the American College of Radiology and the American Association of Physicists in Medicine.

MIDRC organizers recently announced that funding will be available for year three. Interested institutions are encouraged to review the necessary steps to participate in this initiative.

Members of the medical community can attend MIDRC virtual seminars scheduled on the third Tuesday of every month at 2:00 p.m. CT. The seminar series offers an opportunity to hear directly from the MIDRC team and features research presentations from MIDRC investigators on new and noteworthy advances. Sessions are held online and include live Q&A for all attendees. The next seminar will take place on June 21.

For more information, visit MIDRC.org.

SourceRSNA
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy